Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Entera Bio Ltd. (ENTX : NSDQ)
 
 • Company Description   
Entera Bio Ltd. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of orally delivered molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an oral formulation of parathyroid hormone for hypoparathyroidism and osteoporosis. Entera Bio Ltd. is based in Jerusalem, Israel.

Number of Employees: 27

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.50 Daily Weekly Monthly
20 Day Moving Average: 30,446 shares
Shares Outstanding: 23.70 (millions)
Market Capitalization: $59.25 (millions)
Beta: 1.64
52 Week High: $8.68
52 Week Low: $1.72
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.72% 5.05%
12 Week 26.90% 39.50%
Year To Date -11.19% 9.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
KIRYAT HADASSAH MINRAV BUILDING FIFTH FLOOR
-
JERUSALEM,L3 9112002
ISR
ph: 972-2532-7151
fax: -
investorrelations@enterabio.com http://www.enterabio.com
 
 • General Corporate Information   
Officers
Spiros Jamas - Chief Executive Officer
Gerald Lieberman - Chairman
Dana Yaacov-Garbeli - Chief Financial Officer
Phillip Schwartz - Director
Roger J. Garceau - Director

Peer Information
Entera Bio Ltd. (CORR.)
Entera Bio Ltd. (RSPI)
Entera Bio Ltd. (CGXP)
Entera Bio Ltd. (BGEN)
Entera Bio Ltd. (GTBP)
Entera Bio Ltd. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: M40527109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 23.70
Most Recent Split Date: (:1)
Beta: 1.64
Market Capitalization: $59.25 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.16 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.80 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.00
Price/Cash Flow: -
Price / Sales: 122.93
EPS Growth
vs. Year Ago Period: 69.77%
vs. Previous Quarter: -161.90%
Sales Growth
vs. Year Ago Period: -56.69%
vs. Previous Quarter: -58.79%
ROE
03/31/22 - -27.70
12/31/21 - -59.83
09/30/21 - -116.56
ROA
03/31/22 - -24.38
12/31/21 - -47.53
09/30/21 - -89.70
Current Ratio
03/31/22 - 9.27
12/31/21 - 8.01
09/30/21 - 9.72
Quick Ratio
03/31/22 - 9.27
12/31/21 - 8.01
09/30/21 - 9.72
Operating Margin
03/31/22 - -1,345.02
12/31/21 - -2,134.33
09/30/21 - -3,086.76
Net Margin
03/31/22 - -1,345.02
12/31/21 - -2,134.33
09/30/21 - -3,086.76
Pre-Tax Margin
03/31/22 - -2,847.93
12/31/21 - -2,144.66
09/30/21 - -3,260.61
Book Value
03/31/22 - 0.83
12/31/21 - 0.95
09/30/21 - 1.10
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©